News

LSCD Industry Symposium

Welcome to the LS CancerDiag Industry Symposium at the 2023 CGA-IGC Annual Meeting! A couple of weeks ago, we announced our partnership with The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC). One

... read more

CGA-IGC Partnership Announcement

LS CancerDiag entered a new partnership with The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer As we honored the #HereditaryCancerWeek last week, we took the occasion to announce our partnership with CGA-IGC. The

... read more

Meet our Team: Tea Kuivala

More than theory: Learnings of a master’s student in life science startup Tea Kuivala started working for LS CancerDiag as a part-time employee alongside her studies in genetics and molecular biosciences at the University of

... read more

We have moved to new premises!

LS CancerDiag has new laboratory and office premises in Arabianranta, Helsinki During the Summer, LS CancerDiag moved to a new location in Helsinki. The new premises will serve as the global company headquarters and central

... read more

Meet our CSO, Dr. Minttu Kansikas

Minttu Kansikas, Ph.D., Chief Scientific Officer of LS CancerDiag, is one of the inventors of the method behind the DiagMMR test. She has been inspired by genetics since high school. She has enjoyed the field

... read more

Lynch syndrome in a nutshell

Lynch syndrome genetics and clinical implications The Gastroenterology journal (January 2023) features a review article by Professors Päivi Peltomäki, Minna Nyström, Jukka-Pekka Mecklin, and Toni T. Seppälä titled “Lynch Syndrome Genetics and Clinical Implications”. The

... read more

Invest today!

LS CancerDiag has launched a funding round in collaboration with Springvest

The company aims to raise €5.4M in capital to support the expansion into the United States and introduce DiagMMR® to the largest health care market in the world.